Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 3,41 € ( 9,79 %). Der Median liegt bei 3,52 € ( 6,88 %).
Kaufen |
4 |
Halten |
1
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 8 / 18 |
Levermann-Strategie | -4 / 13 |
Beliebteste Broker
News
- 25.10. - 20:45 Uhr
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR. » Mehr auf globenewswire.com
- 23.10. - 02:15 Uhr
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,700,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions. » Mehr auf globenewswire.com
- 22.10. - 20:01 Uhr
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual terms of the Offering. » Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 6,34 Mio | 425,88% |
Bruttoeinkommen | 5,62 Mio | 366,58% |
Nettoeinkommen | 2,71 Mio | 66,15% |
EBITDA | 3,06 Mio | 63,37% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 383,92 Mio € |
Anzahl Aktien | 103,20 Mio |
52 Wochen-Hoch/Tief | 4,34 € - 1,11 € |
Dividenden | Nein |
Beta | 0,25 |
KGV (PE Ratio) | 14,16 |
KGWV (PEG Ratio) | 0,78 |
KBV (PB Ratio) | 9,25 |
KUV (PS Ratio) | 24,97 |
Unternehmensprofil
ProQR Therapeutics N.V., ein biopharmazeutisches Unternehmen, beschäftigt sich mit der Entdeckung und Entwicklung von RNA-basierten Therapeutika für die Behandlung von genetischen Erkrankungen. Es entwickelt in erster Linie Sepofarsen, das sich in der klinischen Phase II/III-Studie Illuminate zur Behandlung der kongenitalen Leber-Amaurose 10 befindet, und Ultevursen, das sich in der klinischen Phase II/III-Studie zur Behandlung der USH2A-vermittelten Retinitis pigmentosa und des Usher-Syndroms befindet. Das Unternehmen befasst sich auch mit der Entwicklung der Axiomer RNA-Base-Editing-Plattformtechnologie. Es hat eine Lizenzvereinbarung mit dem Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc. und dem Leiden University Medical Center sowie eine Lizenz- und Forschungskooperation mit Eli Lilly and Company für die Entdeckung, Entwicklung und Vermarktung potenzieller neuer Medikamente für genetische Störungen der Leber und des Nervensystems. ProQR Therapeutics N.V. wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in Leiden, Niederlande.
Name | ProQR Therapeutics |
CEO | Daniel Anton de Boer |
Sitz | Leiden,
Niederlande |
Website | |
Industrie | Biotechnologie |
Börsengang | 18.09.2014 |
Mitarbeiter | 156 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | PRQR |
Frankfurt | 0PQ.F |
Düsseldorf | 0PQ.DU |
München | 0PQ.MU |
Assets entdecken
Shareholder von ProQR Therapeutics investieren auch in folgende Assets